Loading
Chickenpox Vaccine / Global Burden of Disease · Journal article
Human Vaccines & Immunotherapeutics · September 2, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a secondary analysis of Global Burden of Disease 2021 data using machine learning to forecast varicella incidence, prevalence, and DALYs in children aged 5–9 years through 2030. The study projects a global decline in incidence and DALYs but persistent regional disparities; however, it cannot isolate vaccine effects because vaccination coverage and cohort-level immunization data are absent, limiting causal inference on policy effectiveness.
Retrospective secondary analysis with machine learning-based predictive modelling. Children aged 5–9 years globally, stratified by geographic region. No specific eligibility criteria, inclusion/exclusion criteria, or setting details provided.. Intervention: Varicella vaccination policy tier (higher tier associated with lower DALYs); no active intervention delivery described.. Global; analysis included Southeast Asia, South Asia, Asian and Pacific Island nations, and sub-Saharan Africa as key regions..
Global varicella incidence in children aged 5–9 y rose from 1,028.46/100,000 (1990) to 1,048.24/100,000 (2021), then projected to fall to 897.01/100,000 by 2030. Prevalence increased from 30.81/100,000 (1990) to 31.07/100,000 (2021), projected to 28.96/100,000 by 2030. DALYs declined from 21.09/100,000 (1990) to 12.36/100,000 (2021), projected to 11.71/100,000 by 2030.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and public health planners should note the global declining trend in varicella burden through 2030, but recognize that regional disparities are expected to persist. The finding that higher vaccination program tier associates with lower DALYs is suggestive but not causal; direct evaluation of vaccination coverage and cohort-level immunization effects is needed before using this model to guide coverage or policy decisions.
A modelling study using machine learning to project future disease burden; lacks direct clinical outcomes, relies on historical registry data and predictive algorithms rather than intervention trials, and acknowledges critical data limitations that prevent causal inference on vaccine effects.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and public health planners should note the global declining trend in varicella burden through 2030, but recognize that regional disparities are expected to persist. The finding that higher vaccination program tier associates with lower DALYs is suggestive but not causal; direct evaluation of vaccination coverage and cohort-level immunization effects is needed before using this model to guide coverage or policy decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Varicella remains a common childhood infection worldwide. Understanding long-term trends and identifying key determinants of disease burden are essential for informing vaccination strategies and public health planning. Data were obtained from the Global Burden of Disease (GBD) 2021 study and the global varicella vaccination policy information. Extreme Gradient Boosting (XGBoost) model was trained to predict the disease burden for 2030. This model estimated the incidence, prevalence, and disability-adjusted life years (DALYs) for varicella among children aged 5-9 y worldwide. Shapley Additive exPlanations (SHAP) was employed to identify key factors and inform public health strategies. From 1990 to 2021, the rate of global incidence rose from 1,028.46/100,000 to 1,048.24/100,000, prevalence from 30.81/100,000 to 31.07/100,000, and DALYs declined from 21.09/100,000 to 12.36/100,000. By 2030, these metrics are projected to fall to 897.01/100,000, 28.96/100,000, and 11.71/100,000, respectively. From 1990 through 2030, Southeast and South Asia had the highest varicella incidence, Asian and Pacific Island nations had the highest prevalence, and sub-Saharan Africa and South Asia had the highest DALYs. SHAP identified population as the strongest predictor (mean absolute SHAP value: 0.167 for incidence and 0.103 for prevalence), and higher vaccination program tier may be associated with lower DALYs. Varicella burden among children aged 5-9 y has declined globally, but model projections indicate that regional disparities will persist. The lack of vaccination coverage and cohort-level immunization data limits interpretation of vaccine effects; future studies should incorporate both coverage and cohort exposure information to strengthen policy evaluation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.